Arcus Biosciences (RCUS) Price & Analysis

Compare

531 Followers

RCUS Stock Chart & Stats

$25.56

-$0.04(-0.26%)

At close: Jan 08 4:00 PM EST

$25.56

-$0.04(-0.26%)

Day’s Range― - ―

52-Week Range$6.50 - $26.04

Previous CloseN/A

Volume107.84K

Average Volume (3M)1.85M

Market Cap

$3.16B

Enterprise Value$728.40M

Total Cash (Recent Filing)$831.00M

Total Debt (Recent Filing)$111.00M

Price to Earnings (P/E)―

Beta1.92

Next Earnings

Feb 25, 2026

EPS Estimate

-1.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.27

Shares Outstanding123,728,540

10 Day Avg. Volume1,790,726

30 Day Avg. Volume1,846,164

Financial Highlights & Ratios

PEG Ratio0.19

Price to Book (P/B)2.77

Price to Sales (P/S)5.20

P/FCF Ratio-7.62

Enterprise Value/Market Cap0.23

Enterprise Value/Revenue3.04

Enterprise Value/Gross Profit3.06

Enterprise Value/Ebitda-2.26

Forecast

1Y Price Target

$28.38

Price Target Upside11.03% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering11

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessThe LITESPARK-011 trial increases confidence in the PEAK-1 trial being positive, as both belzutifan and casdatifan are HIF2α inhibitors.

Pipeline ExpansionThe LITESPARK-022 data provide a positive readthrough for the HIF2α class and suggest additional expansion opportunities for the cas development program.

Treatment Regimen AdvantageThe PEAK-1 regimen is viewed as favorable given that cabo is the preferred TKI for RCC treatment and cas + cabo requires fewer pills compared to belzutifan + lenva.

Bears Say

Clinical Success UncertaintySkepticism remains, with these assets yet to see late-stage clinical success and/or facing unclear commercial paths.

Market FragmentationThere’s more investor uncertainties over whether the team can achieve its expansive commercial plans in RCC due to a fragmented market and lack of a commercial partner.

Valuation ChallengesIt's likely to take a while before investors attribute much value to the portfolio due to clinical uncertainties and the relatively higher costs of development.

Arcus Biosciences News

Arcus Biosciences price target raised to $26 from $17 at BofA

BofA raised the firm’s price target on Arcus Biosciences (RCUS) to $26 from $17 and keeps a Neutral...

13h ago

RCUS

Arcus Biosciences 13.7M share Spot Secondary priced at $18.25

The deal range was $18.25-$18.75. Leerink and Goldman Sachs acted as joint book running managers for the offering....

29d ago

RCUS

Arcus Biosciences TBA Spot Secondary; price range $18.25-$18.75

Leerink and Goldman Sachs are acting as joint book running managers for the offering. Published first on TheFly...

29d ago

RCUS

Arcus Biosciences announces common stock offering, no amount given

Arcus Biosciences (RCUS) announced that it has commenced an underwritten public offering of its common stock. All of...

29d ago

RCUS

Arcus Biosciences price target raised to $16 from $14 at Goldman Sachs

Goldman Sachs analyst Salveen Richter raised the firm’s price target on Arcus Biosciences (RCUS) to $16 from $14...

30d ago

RCUS

Arcus Biosciences Completes Successful Stock Offering

Arcus Biosciences ( ($RCUS) ) just unveiled an update. Arcus Biosciences, Inc. recently completed a public offering of...

25d ago

RCUS

Arcus Biosciences price target raised to $35 from $33 at Wedbush

Wedbush raised the firm’s price target on Arcus Biosciences (RCUS) to $35 from $33 and keeps an Outperform...

1M ago

RCUS

Arcus Biosciences price target raised to $56 from $54 at Citi

Citi raised the firm’s price target on Arcus Biosciences (RCUS) to $56 from $54 and keeps a Buy...

1M ago

RCUS

Arcus Biosciences price target raised to $28 from $24 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Arcus Biosciences (RCUS) to $28 from $24 and keeps a...

1M ago

RCUS

Arcus Biosciences Reports Promising Q3 2025 Results

Arcus Biosciences ( ($RCUS) ) has released its Q3 earnings. Here is a breakdown of the information Arcus...

1M ago

RCUS

Arcus Biosciences reports Q3 EPS ($1.27), consensus ($1.29)

Reports Q3 revenue $30M, consensus $20.3M. “Data from the ARC-20 study demonstrate that casdatifan has a best-in-class profile,...

1M ago

RCUS

Arcus Biosciences Advances Cancer Treatment with AB801 Study

Arcus Biosciences (($RCUS)) announced an update on their ongoing clinical study. Arcus Biosciences is conducting a clinical study...

1M ago

RCUS

Arcus Biosciences Advances Phase 3 Trial for Renal Cell Carcinoma

Arcus Biosciences (($RCUS)) announced an update on their ongoing clinical study. Arcus Biosciences is conducting a Phase 3...

1M ago

RCUS

Arcus Biosciences’ Promising Phase 1 Study on Renal Cell Carcinoma

Arcus Biosciences (($RCUS)) announced an update on their ongoing clinical study. Arcus Biosciences is conducting a Phase 1...

1M ago

RCUS

RCUS FAQ

What was Arcus Biosciences Inc’s price range in the past 12 months?

Arcus Biosciences Inc lowest stock price was $6.50 and its highest was $26.04 in the past 12 months.

What is Arcus Biosciences Inc’s market cap?

Arcus Biosciences Inc’s market cap is $3.16B.

When is Arcus Biosciences Inc’s upcoming earnings report date?

Arcus Biosciences Inc’s upcoming earnings report date is Feb 25, 2026 which is in 88 days.

How were Arcus Biosciences Inc’s earnings last quarter?

Arcus Biosciences Inc released its earnings results on Oct 28, 2025. The company reported -$1.27 earnings per share for the quarter, beating the consensus estimate of -$1.31 by $0.04.

Is Arcus Biosciences Inc overvalued?

According to Wall Street analysts Arcus Biosciences Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Arcus Biosciences Inc pay dividends?

Arcus Biosciences Inc does not currently pay dividends.

What is Arcus Biosciences Inc’s EPS estimate?

Arcus Biosciences Inc’s EPS estimate is -1.14.

How many shares outstanding does Arcus Biosciences Inc have?

Arcus Biosciences Inc has 123,728,540 shares outstanding.

What happened to Arcus Biosciences Inc’s price movement after its last earnings report?

Arcus Biosciences Inc reported an EPS of -$1.27 in its last earnings report, beating expectations of -$1.31. Following the earnings report the stock price went up 2.062%.

Which hedge fund is a major shareholder of Arcus Biosciences Inc?

Currently, no hedge funds are holding shares in RCUS

Arcus Biosciences Stock Smart Score

Outperform

Fundamentals

Return on Equity

-68.13%

Trailing 12-Months

Asset Growth

-22.20%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Arcus Biosciences Inc

Arcus Biosciences (RCUS) is a clinical-stage biotechnology company focused on developing innovative therapies for cancer treatment. The company specializes in the discovery and development of novel immuno-oncology agents, particularly small molecules that target key pathways in the immune system to enhance antitumor responses. Arcus is primarily engaged in the research and development of its proprietary drug candidates, including its lead product candidates in various stages of clinical trials aimed at treating different types of cancer.

Arcus Biosciences (RCUS) Earnings & Revenues

Historic Earnings Reports

RCUS Stock 12 Month Forecast

Average Price Target

$28.38

▲(11.03% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","57":"$57","18.75":"$18.75","31.5":"$31.5","44.25":"$44.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$56.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$28.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,18.75,31.5,44.25,57],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.72,22.51076923076923,25.30153846153846,28.092307692307692,30.88307692307692,33.673846153846156,36.464615384615385,39.255384615384614,42.04615384615384,44.83692307692308,47.62769230769231,50.41846153846154,53.20923076923077,{"y":56,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.72,20.386153846153846,21.052307692307693,21.718461538461536,22.384615384615383,23.05076923076923,23.716923076923077,24.38307692307692,25.049230769230768,25.715384615384615,26.38153846153846,27.04769230769231,27.713846153846156,{"y":28.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.72,19.279999999999998,18.84,18.4,17.96,17.52,17.08,16.64,16.2,15.76,15.32,14.879999999999999,14.440000000000001,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.5,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.94,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.89,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.9,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.89,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.71,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.36,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.81,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.48,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.72,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >